Application of pharmacogenomics in supportive oncology: a patient journey

References

• 1. Van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J. Pain Symptom Manage. 51(6), 1070–1090.e9 (2016).
  MedlineGoogle Scholar
• 2. Krebber AM, Buffart LM, Kleijn G et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology 23 (2), 121–130 (2014).
  Medline CASGoogle Scholar
• 3. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 363(8), 733–742 (2010).
  Medline CASGoogle Scholar
• 4. Chanfreau-Coffinier C, Hull LE, Lynch JA et al. Projected prevalence of actionable pharmacogenetic variants and level A drugs prescribed among US Veterans Health Administration pharmacy users. JAMA Netw. Open 2(6), e195345 (2019).
  MedlineGoogle Scholar
• 5. Wang L, Scherer SE, Bielinski SJ et al. Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: the Mayo–Baylor RIGHT 10K Study. Genet. Med. 24(5), 1062–1072 (2022).
  MedlineGoogle Scholar
• 6. US FDA. Table of pharmacogenetic associations (2022). www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations
  Google Scholar
• 7. Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. The Clinical Pharmacogenetics Implementation Consortium: 10 years later. Clin. Pharmacol. Ther. 107(1), 171–175 (2020).
  MedlineGoogle Scholar
• 8. Andersen RL, Johnson DJ, Patel JN. Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways. Pharmacogenomics 17(4), 417–434 (2016).
  CASGoogle Scholar
• 9. Crews KR, Monte AA, Huddart R et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin. Pharmacol. Ther. 110(4), 888–896 (2021).
  Medline CASGoogle Scholar
• 10. Theken KN, Lee CR, Gong L et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin. Pharmacol. Ther. 108(2), 191–200 (2020).
  MedlineGoogle Scholar
• 11. Hicks JK, Bishop JR, Sangkuhl K et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther. 98(2), 127–134 (2015).
  Medline CASGoogle Scholar
• 12. Hicks JK, Sangkuhl K, Swen JJ et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin. Pharmacol. Ther. 102(1), 37–44 (2017).
  Medline CASGoogle Scholar
• 13. National Comprehensive Cancer Network. Distress management (version 2.2022) (2022). www.nccn.org/guidelines/guidelines-detail?category=3&id=1431
  Google Scholar
• 14. Association for Molecular Pathology. Practice guidelines (2022). www.amp.org/clinical-practice/practice-guidelines
  Google Scholar
• 15. Patel JN, Boselli D, Jandrisevits EJ et al. Potentially actionable pharmacogenetic variants and symptom control medications in oncology. Support. Care Cancer 29(10), 5927–5934 (2021).
  MedlineGoogle Scholar
• 16. Reizine N, Danahey K, Schierer E et al. Impact of CYP2D6 pharmacogenomic status on pain control among opioid-treated oncology patients. Oncologist 26(11), e2042–e2052 (2021).
  Medline CASGoogle Scholar
• 17. Patel JN, Boselli D, Hamadeh IS et al. Pain management using clinical pharmacy assessments with and without pharmacogenomics in an oncology palliative medicine clinic. JCO Oncol. Pract. 16(2), e166–e174 (2020).
  MedlineGoogle Scholar
• 18. Patel JN, Boselli D, Symanowski J et al. Pilot study of multi-gene pharmacogenetic testing for pain management in oncology palliative medicine. Pharmacogenomics 22(12), 737–748 (2021).
  CASGoogle Scholar
• 19. Patel JN, Arnall J, Jandrisevits E et al. Pharmacogenomics-guided supportive oncology: a tale of two trials. Contemp. Clin. Trials 105, 106391 (2021).
  MedlineGoogle Scholar
• 20. Mosley SA, Hicks JK, Portman DG et al. Design and rationale for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp. Clin. Trials 68, 7–13 (2018).
  MedlineGoogle Scholar